|
|
| | PRT062607 (Hydrochloride) Basic information |
| Product Name: | PRT062607 (Hydrochloride) | | Synonyms: | PRT062607 (Hydrochloride);PRT062607 (P505-15, BIIB057) HCl;2-[[(1R,2S)-2-AMinocyclohexyl]aMino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]aMino]-5-pyriMidinecarboxaMide Hydrochloride;PRT062607 (P505-15 HCL);PRT062607 HCL;2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide hydrochloride (1:1);PRT-2607 HCl;P505-15 HCl salt, PRT062607 HCl salt,PRT-2607 HCl salt, BIIB-057 HCl salt | | CAS: | 1370261-97-4 | | MF: | C19H24ClN9O | | MW: | 429.90656 | | EINECS: | | | Product Categories: | Inhibitors;Pharmaceuticals, Intermediates & Fine Chemicals | | Mol File: | 1370261-97-4.mol |  |
| | PRT062607 (Hydrochloride) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≥21.5 mg/mL in DMSO; insoluble in EtOH; ≥83.2 mg/mL in H2O with gentle warming | | form | solid |
| | PRT062607 (Hydrochloride) Usage And Synthesis |
| Uses | PRT062607 (Hydrochloride)acts as a novel spleen tyrosine kinase (syk) inhibitors used in the treatment of leukemia. | | target | Syk |
| | PRT062607 (Hydrochloride) Preparation Products And Raw materials |
|